ARCHIVES

DCT Board Okays Extension Of Phase 1 Master Agreements, Increase To $4 Million

This article is from The Cancer Letter archive.

Vol. 13 No. 09 | February 27, 1987

Download PDF Visit The Full Archive

Related Articles

Gleevec Better Than Interferon For Newly Diagnosed CML

May 31, 2002

Sustained-Release Leuprolide Under Study In Phase III Trial.

June 30, 2000

FDA Concerned About Data-Dredging In Drug-Diagnostic Applications

January 30, 2009

Paraplatin Lengthened TTP In HER2+ Advanced Breast Ca

January 31, 2003

Duke Scientists Develop 3D Mammography Using CT

February 24, 2006

NCI Cooperative Group Clinical Trials Approved

February 26, 2010